This article has no abstract; the first 100 words appear below.
Cardiogenic shock occurs in approximately 5% of patients with an acute coronary syndrome — usually, but not always, after ST-segment elevation myocardial infarction. If a large amount of myocardial tissue has become ischemic or injured, pump failure and reduced blood flow to vital organs occur. Urgent percutaneous coronary intervention (PCI) of the culprit lesion is currently the only therapy associated with a significant decrease in mortality.1 No other intervention with a device or pharmacologic agent has shown a significant benefit, and as a consequence, mortality has plateaued at 50% in recent years. On angiography performed during the acute phase, clinically . . .